Identification and quantitation of interferon-γ producing T cells in psoriatic lesions: Localization to both CD4+ and CD8+ subsets

Journal of Investigative Dermatology

Volumn 111, Issue 6, 1998, Pages 1072-1078

  Szabo, Sarolta K ^a,b,d   Hammerberg, Craig ^a   Yoshida, Yuichi ^a   Bata Csorgo, Zsuzsanna ^b   Cooper, Kevin D ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IFN psoriasis; T cells

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; T LYMPHOCYTE SUBPOPULATION;

EID: 0032465258     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00419.x     Document Type: Article

References (61)

1. Atamas SP, Choi J, Yurovsky VV, White B: An alternative splice variant of human IL-4, IL-4δ2, inhibits IL-4 stimulated T cell proliferation. J Immunol 156:435-441, 1996
2. Baadsgaard O, Tong P, Elder JT, et al: UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol 95:275-282, 1990
3. Baker BS, Fry L: Autoreactive proliferative responses by T-cell lines isolated from psoriatic lesions. J Invest Dermatol 97:606, 1991
4. Baker BS, Fry L: The immunology of psoriasis. Br J Dermatol 126:1-9, 1992
5. Baker BS, Swain AF, Fry L, Valdimarsson H: Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110:555-564, 1984
6. Baker BS, Swain AF, Griffiths CEM, Leonard JN, Fry L, Valdimarsson H: Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol 61:526-534, 1985
7. Baker BS, Powles AV, Lambert S, Valdimarsson H, Fry L: A prospective study of the Koebner reaction and T lymphocytes in uninvolved psoriatic skin. Acta Derm Venereol (Stockh) 68:430-434, 1988a
8. Baker BS, Powles AV, Valdimarsson H, Fry L: An altered response by psoriatic keratinocytes to gamma interferon. Scan J Immunol 28:735-740, 1988b
9. Baker BS, Bokth S, Powles A, Garioch JJ, Lewis H, Valdimarsson H, Fry L: Group A streptococcal antigen-specific T lymphocytes in guttate psoriatic lesions. Br J Dermatol 128:493-499, 1993
10. Barker JNWN, Karabin GD, Stoof TJ, Sarma VJ, Dixit VM, Nickoloff BJ: Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. J Dermatol Sci 2:106-111, 1991
11. Basham TY, NickolofF BJ, Merigan TC: Recombinant gamma interferon induces HLA-DR expression on cultured keratinocytes. J Invest Dermatol 83:88-92, 1984
12. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD: Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med 178:1271-1281, 1993
13. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD: Intralesional T-lymphocyte activation as a mediator of psoriatic hyperplasia. J Invest Dermatol 105:89S-94S, 1995a
14. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD: Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95:317-327, 1995b
15. Bata-Csorgo Z, Cooper KD, Ting K, Voorhees JJ, Hammerberg C: Fibronectin and α5 integrin regulate keratinocyte cell cycling: a mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J Clin Invest 101:1509-1518, 1998
16. Boehncke W-H, Zollner TM, Dressel D, Kaufmann R: Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol 24:1-7, 1997
17. de Boer OJ, van der Loos CM, Hamerlinck F, Bos JD, Das PK: Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. Arch Dermatol Res 286:87-96, 1994
18. Bos JD, Zonneveld I, Das PK, Krieg SR, van der Loos CM, Kapsenberg ML: The skin immune system (SIS): Distribution and immunophenotype of lymphocyte subpopulation in normal human skin. J Invest Dermatol 88:569-573, 1987
19. Bos JD, Hagenaars C, Das PK, Krieg SR, Voom WJ, Kapsenberg ML: Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 281:24-30, 1989
20. Chang JCC, Smith LR, Froning KJ, et al: CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci USA 91:9282-9286, 1994
21. Christophers E, Parzefall R, Braun-Falco O: Initial events in psoriasis: Quantitative assessment. Br J Dermatol 89:327-334, 1973
22. Cooper KD, Voorhees JJ, Fisher GJ, Chan LS, Gupta AK, Baadsgaard O: Effects of cyclosporine on immunologic mechanisms in psoriasis. J Am Acad Dermatol 23:1318-1328, 1990
23. Duvic M: Immunology of AIDS related to psoriasis. J Invest Dermatol 95:38S-40S, 1990
24. Ellis CN, Gorsulowsky DC, Hamilton TA, et al: Cyclosporine improves psoriasis in a double-blind study. JAMA 256:3110-3116, 1986
25. Fierlbeck G, Rassner G, Muller C: Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 126:351-355, 1990
26. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS: T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 109:283-288, 1997
27. Gottlieb AB, Luster AD, Posnett DN, Carter DM: Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 168:941-948, 1988
28. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworm TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1:442-147, 1995
29. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker US, Valdimarsson H: Clearance of psoriasis with low dose cyclosporin. Br Med J Clin Res 293:731-732, 1986
30. Griffiths CEM, Voorhees JJ, Nickoloff BJ: Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 20:617-629, 1989a
31. Griffiths CEM, Voorhees JJ, Nickoloff BJ: Gamma interferon induces different keratinocyte cellular patterns of expression of HLA-DR and DQ and intercellular adhesion molecule-I (ICAM-I) antigens. Br J Dermatol 120:1-7, 1989b
32. Gupta AK, Baadsgaard O, Ellis CN, Voorhees JJ, Cooper KD: Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch Dermatol Res 281:219-226, 1989
33. Hammar H, Shao-Qiu G, Johannesson A, Sundkvist K-G, Biberfeld P: Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion. J Invest Denn 83:416-420, 1984
34. + lymphocytopenia. Br J Dermatol 136:930-932, 1997
35. Henseler T, Christophers E: Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450-456, 1985
36. Javier AF, Bata-Csorgo Z, Ellis CN, Kang S, Voorhees JJ, Cooper KD: Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest 99:2094-2099, 1997
37. Kaneko F, Suzuki M, Takiguchi Y, Itoh N, Minagawa T: Immunohistopathologic studies in the development of psoriatic lesion influenced by gamma-interferon and the producing cells. J Dermatol Sci 1:425-434, 1990
38. Krueger JG, Wolfe JT, Nabeya RT, et al: Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 182:2057-2068, 1995
39. Leung DYM, Walsh P, Giorno R, Norris DA: A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 100:225-228, 1993
40. Livden JK, Nilsen R, Bjerke JR, Matre R: In: situ localization of interferons in psoriatic lesions. Arch Dermatol Res 281:392-397, 1989
41. Markey AC, Allen MH, Pitzalis C, MacDonald DM: T-cell inducer populations in cutaneous inflammation: a predominance of T helper-inducer lymphocytes (THi) in the infiltrate of inflammatory dermatoses. Br J Dermatol 122:325-332, 1990
42. Morganroth GS, Chan LS, Weinstein GD, Voorhees JJ, Cooper KD: Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol 96:333-340, 1991
43. Morhenn VB, Abel EA, Mahrle G: Expression of HLA-DR antigen in skin from patients with psoriasis. J Invest Dermatol 78:165-168, 1982
44. Moss P, Charmley P, Mulvihill E, et al: The repertoire of T cell antigen receptor b-chain variable regions associated with psoriasis vulgaris. J Invest Dermatol 109:14-19, 1997
45. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB: Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Lab Invest 51:697-701, 1984
46. Nickoloff BJ, Mitra RS, Elder JT, Fisher GJ, Voorhees JJ: Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. Br J Dermatol 121:161-174, 1989
47. Nikaein A, Phillips C, Gilbert SC, Savino D, Silverman A, Stone MJ, Menter A: Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol 96:3-9, 1991
48. Onuma S: Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol 21:223-232, 1994
49. Paukkonen K, Naukkarinen A, Horsmanheimo M: The development of manifest psoriatic lesions is linked with the invasion of CD8 + T Cells and CD11c + macrophages into the epidermis. Arch Dermatol Res 284:375-379, 1992
50. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC: Direct demonstration of cytokine synthesis heterogeneity among human memory/ effector T cells by flow cytometry. Blood 86:1408-1419, 1995
51. Prinz J, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber P, Riethmuller G: Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 338:320-321, 1991
52. Schlaak JF, Buslau M, Jochum W, et al: T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145-149, 1994
53. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150:5321-5329, 1993
54. Solbach W: Tumor-promoting phorbol esters selectively abrogate the expression of the T4 differentiation antigen expressed on normal and malignant (Sezary) T helper lymphocytes. J Exp Med 156:1250-1255, 1982
55. Spetz A-L, Strominger J, Groh-Spies V: T cell subsets in normal human epidermis. Am J Pathol 149:665-674, 1996
56. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701-705, 1993
57. Valdimarsson H, Baker BS, Jonsdottir I, Fry L: Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 7:256-259, 1986
58. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC: T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 24:2377-2382, 1994
59. Weinshenker BG, Bass BH, Ebers GC, Rice GPA: Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatment. J Am Acad Dermatol 20:1132-1133, 1989
60. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887, 1996
61. Yoshimura N, Oka T: FK 506, a new immunosuppressive agent: a review. J Immunol Immunopharmacol 10:32-36, 1990